Use of i.v. immunoglobulins in neurology. Evidence-based consensus

Der Nervenarzt
M Stangel, R Gold

Abstract

Intravenous immunoglobulins (IVIg) have become an alternative immunomodulatory treatment for neurological autoimmune disorders. On the basis of several well conducted placebo-controlled trials evidence is available supporting the efficacy of IVIg. However, of all neurological diseases, IVIg is currently only licensed for Guillain-Barré syndrome. Thus, the off-label use of IVIg has to be focussed although an effective treatment must be made available for the patients, in particular when there is no other treatment alternative. The consensus paper presented here critically discusses the modern studies investigating the use of IVIg in neurological diseases. On the basis of this evidence recommendations for the treatment with IVIg were developed. To achieve a broad and valid consensus, numerous German speaking experts in the field were involved. It is expected that this manuscript will help to ascertain a rational use of IVIg in the future.

Citations

Sep 1, 2008·Therapeutic Advances in Neurological Disorders·Martin Stangel
Aug 8, 2009·Der Nervenarzt·S SchwarzB Storch-Hagenlocher
Jan 6, 2007·Nature Clinical Practice. Neurology·Ralf GoldMarinos C Dalakas
Sep 26, 2006·Journal of Neurology·Martin Stangel, Refik Pul
Sep 26, 2006·Journal of Neurology·Ales Dudesek, Uwe K Zettl
Sep 26, 2006·Journal of Neurology·Juan J Archelos, Franz Fazekas
Jul 11, 2008·Expert Opinion on Biological Therapy·Refik Pul, Martin Stangel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.